---
category: news
title: "Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors"
abstract: "Phase 1b/2a Trial of COTI-2 The ongoing trial of COTI-2 will focus on evaluating COTI-2 as a combination therapy for the potential treatment ... pharmaceutical company that uses proprietary artificial intelligence technologies to pursue a targeted and ..."
publishedDateTime: 2019-06-28T04:38:00Z
sourceUrl: https://www.einpresswire.com/article/489197588/cotinga-pharmaceuticals-doses-first-patient-in-third-cohort-of-phase-1b-2a-combination-trial-of-coti-2-in-solid-tumors
type: article

provider:
  name: EIN Presswire
  id: einpresswire

topics:
  - AI
  - artificial intelligence therapy
---
